CELLDEX THERAPEUTICS INC (CLDX)
US15117B2025 - Common Stock
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside...
Investors Land CLDX Even Cheaper Than Its Secondary Stock Offering
Notable Wednesday Option Activity: CLDX, GOOG, PSFE
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief...
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of...
Celldex prices $400.4M stock offering (NASDAQ:CLDX)
Celldex Therapeutics prices stock offering to raise $400.4M for clinical development of product candidates and general corporate purposes.
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an...
Celldex Therapeutics announces proposed public offering of shares (NASDAQ:CLDX)
Celldex Therapeutics plans to raise $250M through a public offering of its common stock, with an option for underwriters to purchase an additional $37.5M...
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is...
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.
Celldex GAAP EPS of -$0.83 misses by $0.09, revenue of $4.13M beats by $3.27M (NASDAQ:CLDX)
Celldex reports fourth-quarter and year-end 2023 financial results, with revenue of $4.13M beating expectations by $3.27M, but EPS misses by $0.09.
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024;...
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose...
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside...
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results...
Interesting CLDX Put And Call Options For March 15th
Interesting CLDX Put And Call Options For August 2024
Celldex Therapeutics (CLDX) Shares Cross Above 200 DMA
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside...
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.
Celldex stock gains as Wells Fargo upgrades (NASDAQ:CLDX)
Wells Fargo upgrades Celldex Therapeutics (CLDX) after Novartis' positive Phase 3 data for its tyrosine kinase inhibitor remibrutinib. Read more here.